Mosquito-borne diseases are persistent and potentially severe posing a threat to global pandemic preparedness.The risk of mosquito-borne virus transmission is rapidly increasing due to the unprecedented spread of viru...Mosquito-borne diseases are persistent and potentially severe posing a threat to global pandemic preparedness.The risk of mosquito-borne virus transmission is rapidly increasing due to the unprecedented spread of viruses such as dengue and chikungunya,the disruption of global mosquito-borne disease control efforts following the emergence of coronavirus diseases 2019(COVID-19)in 2019,global warming,and human activities.To address this global challenge,various innovative mosquito control technologies are being developed worldwide.This paper summarizes the latest advances in mosquito vector control,focusing on China’s latest mosquito control strategies,to provide insights into implementing novel mosquito-borne disease control measures.展开更多
Dear Editor,The global prevalence of XBB subvariants,known for their significant immune evasion,has driven the development and adaptation of XBB vaccines.Monovalent XBB.1.5 mRNA vaccines have been developed and shown ...Dear Editor,The global prevalence of XBB subvariants,known for their significant immune evasion,has driven the development and adaptation of XBB vaccines.Monovalent XBB.1.5 mRNA vaccines have been developed and shown to provoke robust immune responses against XBB.1.5,EG.5.1,and BA.2.86 following vaccination.1 In June 2023,the XBB.1.5-recombinant COVID-19 trivalent(XBB.1.5+BA.5+Delta)protein vaccine(trivalent XBB.1.5 vaccine)(WestVac Biopharma Co.,Ltd.,China)was approved for emergency use against XBB subvariants.Although preliminary data from the manufacturer suggest neutralization of several earlier Omicron subvariants and XBB.1.5,there is limited real-world evidence,and persisting immune imprinting may affect the induction of antibodies against new SARS-CoV-2 sublineages,2 such as JN.1,which has increased transmissibility and the ability to evade immunity.3 Additionally,subsequent XBB infection after BA.5/BF.7 breakthrough infection does not efficiently induce humoral immunity against JN.1,4 raising questions about the ability of the trivalent XBB.1.5 vaccine to provide adequate protection against this lineage.We measured the neutralizing antibody responses in 32 individuals who experienced a BA.5/BF.7 breakthrough infection and a subsequent XBB infection before and after receiving the trivalent XBB.1.5 vaccination.The detailed demographic information of the study participants and their vaccination and infection histories are described in the Supplementary Methods.展开更多
文摘Mosquito-borne diseases are persistent and potentially severe posing a threat to global pandemic preparedness.The risk of mosquito-borne virus transmission is rapidly increasing due to the unprecedented spread of viruses such as dengue and chikungunya,the disruption of global mosquito-borne disease control efforts following the emergence of coronavirus diseases 2019(COVID-19)in 2019,global warming,and human activities.To address this global challenge,various innovative mosquito control technologies are being developed worldwide.This paper summarizes the latest advances in mosquito vector control,focusing on China’s latest mosquito control strategies,to provide insights into implementing novel mosquito-borne disease control measures.
基金supported by grants from the National Natural Science Foundation of China(82273692 and 92169207)the Quzhou Science and Technology Bureau(2021K12)。
文摘Dear Editor,The global prevalence of XBB subvariants,known for their significant immune evasion,has driven the development and adaptation of XBB vaccines.Monovalent XBB.1.5 mRNA vaccines have been developed and shown to provoke robust immune responses against XBB.1.5,EG.5.1,and BA.2.86 following vaccination.1 In June 2023,the XBB.1.5-recombinant COVID-19 trivalent(XBB.1.5+BA.5+Delta)protein vaccine(trivalent XBB.1.5 vaccine)(WestVac Biopharma Co.,Ltd.,China)was approved for emergency use against XBB subvariants.Although preliminary data from the manufacturer suggest neutralization of several earlier Omicron subvariants and XBB.1.5,there is limited real-world evidence,and persisting immune imprinting may affect the induction of antibodies against new SARS-CoV-2 sublineages,2 such as JN.1,which has increased transmissibility and the ability to evade immunity.3 Additionally,subsequent XBB infection after BA.5/BF.7 breakthrough infection does not efficiently induce humoral immunity against JN.1,4 raising questions about the ability of the trivalent XBB.1.5 vaccine to provide adequate protection against this lineage.We measured the neutralizing antibody responses in 32 individuals who experienced a BA.5/BF.7 breakthrough infection and a subsequent XBB infection before and after receiving the trivalent XBB.1.5 vaccination.The detailed demographic information of the study participants and their vaccination and infection histories are described in the Supplementary Methods.
